Bibliography
- CARLSSON A, HANSSON LO, WATERS N, CARLSSON ML:Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life ScL (1997) 61:75–94.
- CLERC GE, RUIMY P, VERDEAU-PALLES J: A double-blindcomparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. The Ven lafax in e French Inpatient Study Group. Int. Psychopharmacol. (1994) 9:139–143.
- CONNERS CK, CASAT CD, GUALTIERI CT et al.: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:1314–1321.
- McKERNAN R, ROSAHL TW, REYNOLDS D S etal.: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor al subtype. Nature Neuroscience (2000) 3:587–592.
- MADHAV TR, PEI Q, GRAHAME-SMITH DG, ZETTERSTOMT: Repeated electroconvulsive shock promotes the sprouting of serotonergic axons in the lesioned rat h ip p o campus. Neuroscience (2000) 97:677–683.
- MAGISTRETTI PJ, PELLERIN L, ROTHMAN DL, SHULMAN RG: Energy on demand. Science (1999) 283:496–497.
- MARSDEN CA, REX A (Eds.): Special issue: transgenics and psychopharmacology. Rev. Neuroscience (2000) 11:1–74.
- MORA PO, NETTO CF, GRAEFF FG: Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem. Behav. (1997) 58:1051–1105.
- NEEDHAM PL, HOLTOM PE, BUTLER SA, BENNETT GW, ASPLEY S: Neurotensin: Anti-psychotic or psycho-metric? Schizophrenia Res. (2000) (In Press).
- PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONSECU F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. (2000) 21:218–224.